Norfenfluramine
Names | |
---|---|
Preferred IUPAC name
1-[3-(Trifluoromethyl)phenyl]propan-2-amine | |
Other names
3-Trifluoromethylamphetamine
| |
Identifiers | |
3D model (
JSmol ) |
|
ChemSpider | |
IUPHAR/BPS |
|
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C10H12F3N | |
Molar mass | 203.208 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Norfenfluramine, or 3-trifluoromethylamphetamine, is a never-marketed
cardiac fibroblasts on the tricuspid valve, known as cardiac fibrosis.[1] This side effect led to the withdrawal of fenfluramine as an anorectic agent worldwide, and to the withdrawal of benfluorex in Europe,[2] as both fenfluramine and benfluorex form norfenfluramine as an active metabolite. It is a human TAAR1 agonist.[3]
See also
- Fenfluramine
- Benfluorex
- Norfenfluramine is the precursor to flucetorex
References
- S2CID 30906680.
- ^ "European Medicines Agency recommends withdrawal of benfluorex from the market in European Union" (PDF). European Medicines Agency. 2009-12-18. Archived from the original (PDF) on 2009-12-22.
- PMID 22037049.